Cologne

• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Ended recruitment
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended recruitment
  2022-502686-24-00 5 2023-11-22 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi … Ended recruitment
  2023-503294-37-00 5 2023-11-20 Osteogenesis Imperfecta
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended recruitment
  2023-503655-10-00 5 2023-11-20 Systemic Lupus Erythematosus (SLE).
• A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr … Ended recruitment
  2022-502102-32-00 5 2023-11-16 Primary Immunoglobulin A (IgA) Nephropathy
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended recruitment
  2022-502105-15-00 4 2023-10-20 Systemic lupus erythematosus
• SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended recruitment
  2022-502012-37-00 5 2023-10-06 Advanced Hepatocellular Carcinoma
• Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended recruitment
  2023-503652-27-00 5 2023-10-06 Melanoma
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended recruitment
  2023-505054-17-00 6 2023-09-15 metastatic TTF-1 negative lung adenocarcinoma
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended recruitment
  2023-508499-12-00 5 2023-05-17 Systemic Lupus Erythematosus
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A study to test product setrusumab in subjects with brittle bone syndrome. Ended recruitment
  2024-510919-29-00 10 2023-05-08 Osteogenesis imperfecta (OI)
• A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen … Ended recruitment
  2024-512890-28-00 5 2023-03-20 Primary immune thrombocytopenia (ITP)
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended recruitment
  2023-509825-38-00 5 2022-12-01 Metastatic Non–Small Cell Lung Cancer
• OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended recruitment
  2024-511581-37-00 6 2022-11-25 Respiratory Tract Infections with Wheezing Lower Respiratory Illness
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis

Showing 337–360 of 577 trials